Elan turns down Royalty Pharma's $6.4B takeover offer

05/28/2013 | Bloomberg Businessweek · PharmaTimes (U.K.)

Elan has rejected Royalty Pharma's renewed bid, which values the firm at around $6.4 billion compared with a previous offer of $5.7 billion. The offer significantly undervalues Elan, Elan Chairman Robert Ingram said. The bid offers compelling value, Royalty has said.

View Full Article in:

Bloomberg Businessweek · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC